Long Term Use of SAVI SCOUT: Pilot Study
Completed · Not applicable
Conditions studied: Breast Diseases
In brief
The purpose of this study is to evaluate the performance of FDA-cleared SAVI SCOUT Breast Localization and Surgical Guidance System (SCOUT) over a longer duration prior to surgery. The device is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue. The SCOUT device standard of care use is placement up to 30 days prior to surgery to assist surgeons in the localization and retrieval of breast/axillary lesions. Routine image-guided methods (Mammography, Ultrasound, and CT) are used. In this study, investigators will assess the longer term placement of the SCOUT device over an extended time (31 - 365 days) in order to address the needs of patients who require neoadjuvant treatment prior to definitive surgery.
Key facts
- Study ID
- NCT03015649
- Run by
- Envision Healthcare Scientific Intelligence, Inc.
- People needed
- 34
- Starts
- 2017-02-03
- Expected to finish
- 2019-04-04
- Last updated by the study team
- 2020-05-11
Who can join
Age: 18 and older, up to 90. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Patient is willing and able to provide informed consent. Patient SCOUT device(s) is placed as part of routine care or study but before neoadjuvant treatment begins.
- Patient is female.
- Patient is between the ages of 18 and 90 years.
- Patient has breast cancer and will undergo neoadjuvant therapy and excision at Memorial Healthcare System.
- Patient is willing and able to comply with all study procedures and be available to follow-up for the duration of the study (1 - 13 months).
- Patient reads or understands English or Spanish.
You may not qualify if…
- Patient is pregnant.
- Patient has pacemaker or implantable defibrillators (These have not been bench tested as of September 2016).
- Patient has known or suspected nickel allergy.
- Patient is scheduled or receiving investigational drugs for neoadjuvant regimen. (This could confound UADE of this device.)
- Patient has any condition that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
- Patient has other malignancy except for adequately treated and cured basal or squamous cancer, curatively treated in situ disease or any other cancer for which the patient has been disease free for greater than or equal to 5 years.
Where it is running
- Envision Physician Scientific Research, Inc. formerly Sheridan Healthcare, Inc. — Plantation, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.